CONTAGIOUS COMMENTS Department of Epidemiology
|
|
- Sara Tucker
- 5 years ago
- Views:
Transcription
1 VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R. Dominguez MD PhD Antibiogram Tables The 2013 Microbiology Laboratory antibiogram is also published within the Bugs and Drugs Handbook. Copies are available from Microbiology or Epidemiology ( ) and internally on the Pathology Webpage at: ( Items of importance from this year s data are highlighted here. With the exception of Stenotrophomonas maltophilia, these changes reflect decreases in susceptibility for the organisms isolated in the CHCO microbiology laboratory. Stenotrophomonas maltophilia demonstrates an increase in trimethoprim-sulfamethoxazole susceptibility. Our percentage matches the rate seen in other institutions nationwide. There is no increase in non-urine ESBL isolation; however a decrease in gentamicin susceptibility is noted among our isolates. Haemophilus influenzae isolates are more ampicillin resistant. Viridans streptococci are significantly more resistant to penicillin. S. anginosus demonstrates a shift to higher MICs with more intermediate interpretations reported. S. aureus susceptibility to clindamycin decreased by about 10% for both MSSA and MRSA. Isolation of VRE increased from one in previous year to five this past year. A footnote was added to Table 2 Indicating that non-meningeal S. pneumoniae infections may be treated with amoxicillin, cefepime, cefotaxime, ceftriaxone, and cefuroxime. Rapid Blood Culture ID Panel (BCID) This spring, the Microbiology Lab implemented the BCID panel which is a multiplex PCR consisting of 8 gram positive targets, 11 gram negative targets, 5 yeast targets and 3 resistance mechanisms. When blood culture bottles arrive in the Microbiology Lab, they are placed on the Bactec blood culture analyzer and continuously monitored during their 5 day incubation. When the blood culture becomes positive, a Gram stain is performed and a phone call is made within 30 minutes to a physician caring for the patient to report the critical value in Microbiology. Then, the blood culture bottle is tested using the BCID panel. Within about an hour, results are reported with a second phone call to the clinician caring for the patient. In many cases, the organism will be definitively identified by BCID. In the case of an organism that is not represented on the panel, a report will be issued that indicates BCID organisms were not identified. In the case of mixed blood cultures, one organism may be detected and a second may not, yielding variable results. The test is kept in preliminary status until the traditional culture result is available. Occasionally, a corrected report may be issued when definitive culture results do not correlate with the BCID. The intent of performing and reporting the BCID is to allow the clinician the fastest results available, allowing for appropriate antimicrobial adjustments so that patients are treated appropriately in the best available time frame. Rapid reporting of organism identification holds the potential to bring savings to the institution through de-escalation of antimicrobials and avoiding readmission of patients with positive blood cultures deemed likely contaminants. VOLUME XXIX NUMBER 3 November 2014 Page 1
2 Antimicrobial Stewardship Combines Forces with Microbiology Antimicrobial Stewardship works closely with the microbiology laboratory in an effort to improve patient care. The stewards work to decrease antibiotic pressure within CHCO, in order to decrease antimicrobial resistance, C. difficile infections and adverse drug events, and to improve antimicrobial dosing and efficacy. In order to harness maximal benefit from BCID, the second call described above may be placed by one of the antimicrobial stewards; the stewards will report the BCID result, and are available to field general questions on antimicrobial dose and choice. When highly resistant organisms occur, the stewards are available to help with optimal choice and dosing strategies. Sputum Sample Rejection Criteria Criteria for sputum sample rejection criteria are currently in place. When submitted for bacterial culture, sputa that contain >10 squamous epithelial cells observed per oil immersion field are rejected. This criteria was established by our accrediting agency and is a marker for oral flora contamination. Culture results from specimens that are heavily contaminated in this way are unreliable and will not be cultured. Specimens for Cystic Fibrosis Culture are exempt from this protocol by special request because they are surveillance cultures designed to isolate certain types of bacteria and results are not typically affected by normal oral flora contamination Annual Antibiogram Tables 1-7 TABLE 1. Antimicrobial Susceptibilities at Children s Hospital Colorado 2013 Staphylococcus (% susceptible) TESTED Oxacillin* Trimethoprim / Sulfa Clindamycin Vancomycin Staph aureus (MSSA) Staph aureus (MRSA) 478 R Staph epidermidis * Includes agents: Nafcillin/Dicloxacillin/Methicillin Oxacillin resistance predicts resistance to ALL beta-lactams (including penicillin, extended spectrum penicillins and cephalosporins (MRSA) Confirmation of MRSA by PBP2 or Microscan Panel Other antimicrobials tested by Microscan panels VOLUME XXIX NUMBER 3 November 2014 Page 2
3 TABLE 2. Antimicrobial Susceptibilities at Children s Hospital Colorado 2013 Streptococcus (% susceptible) Penicillin Cefotaxime S I R S I R S. pneumoniae 1 Meningeal ( ) (10) S. pneumoniae 1 Non-meningeal * 100 Viridans Strep 1 Group - Invasive Strep. anginosus Group 1 - Invasive Beta Strep Group A 1 Invasive (21) S S Beta Strep Group B 1 (10) S 2 S Beta Strep Group B 1 (prenatal screens) 505 S Enterococcus faecalis Enterococcus faecium Vanc Resistant Enterococcus spp. (VRE) ** 5 R R 1 Testing by E-test. Testing by Microscan panel. ( ) = small numbers S = Always susceptible to penicillin, ampicillin and cephalexin. **Five new VRE patient identified in 2013 for therapy choices, ID consult recommended. * S. pneumoniae isolates that are susceptible to penicillin are also susceptible to ampicillin. S. pneumoniae infections may be treated with amoxicillin, cefotaxime, ceftriaxone and cefepime. Cefotaxime susceptibility does not imply susceptibility to oral cephalosporins. Gentamicin Synergy Screen E. faecalis = 94% Susceptible Gentamicin Synergy Screen E. faecium = 91% Susceptible Gentamicin Synergy Screens on VRE isolates show 100% Susceptible at CHCO Combination therapy should be used in serious Enterococcus spp. infection (endocarditis & bacteremia). Gentamicin synergy screen predicts synergy of aminoglycosides with cell wall active agents. Erythromycin Clindamycin Trimethoprim/Sulfa Cefotaxime Ampicillin/ Amoxicillin Vancomycin VOLUME XXIX NUMBER 3 November 2014 Page 3
4 TABLE 3. Antimicrobial Susceptibilities at Children s Hospital Colorado 2013 Gram Negative Organisms, non urine (% susceptible) Ampicillin / Amoxicillin Cefazolin Cefotaxime/ Ceftriaxone Gentamicin Trimethoprim / sulfa Ciprofloxacin Meropenem Cefepime Haemophilus species (29) E. coli Enterobacter cloacae 48 R R Klebsiella pneumoniae 42 R Klebsiella oxytoca (24) R Serratia marcescens (20) R R Citrobacter freundii 35 R R Salmonella species Shigella species* (25) ( ) = small numbers * = Data combined R = Resistant (Intrinsic) Haemophilus spp. tested by E-test. All other testing by Microscan panel. 5 non-urine ESBL producing Enterobacteriaceae were isolated not included in above data. VOLUME XXIX NUMBER 3 November 2014 Page 4
5 TABLE 4. Antimicrobial Susceptibilities at Children s Hospital Colorado 2013 Gram Negative Organisms isolated from Urine (% susceptible) Ampicillin / Amoxicillin Ampicillin/Sulbactam Cephalothin** Cefuroxime Cefotaxime/ Ceftriaxone Gentamicin Nitrofurantoin Trimethoprim / sulfa Ciprofloxacin Ceftazidime Levofloxacin Cefepime E. coli E. coli ESBL* (23) R 4 R R R R R Enterobacter cloacae 39 R R R Klebsiella pneumoniae 104 R R Klebsiella oxytoca 35 R R Proteus mirabilis R Pseudomonas aeruginosa ( ) Small number of isolates R = Resistant (Intrinsic) Testing by Microscan panel **Cephalothin results can be used as a surrogate to predict susceptibility to the oral cephalosporin agents: cefdinir, cefpodoxime, cephalexin. *Note: Patients with ESBL producing organisms isolated from urine who have uncomplicated UTI may respond to therapy with beta-lactam agents. VOLUME XXIX NUMBER 3 November 2014 Page 5
6 TABLE 5. Antimicrobial Susceptibilities at The Children s Hospital 2013 Non-Enterobacteriaceae (% susceptible) Ticarcillin/clavulanic acid Ceftazidime Aztreonam Levofloxacin Tobramycin Meropenem Piperacillin / Tazobactam Minocycline Trimethoprim / Sulfa Ciprofloxacin Gentamicin Cefepime Pseudomonas aeruginosa Non CF CF-mucoid CF-nonmucoid Stenotrophomonas maltophilia R Cystic fibrosis (CF) isolates performed by E-test. Non-CF testing performed by Microscan panel. VOLUME XXIX NUMBER 3 November 2014 Page 6
7 TABLE 6. Antimicrobial Susceptibilities at Children s Hospital Colorado 2013 Candida species (# of isolates susceptible) Antifungal # Tested # Susceptible # SDD # Resistant Amphotericin Micafungin Fluconazole Voriconazole Testing performed by UTHSC at San Antonio Fluconazole comments: SDD - Susceptible Dose Dependent C. glabrata treatment with fluconazole requires maximum dosages when the MIC is < 32 ug/mll, ID consult is recommended. *C. krusei is intrinsically resistant to fluconazole (isolates not tested). Candida spp. isolates included in data: (12 blood isolates) C. albicans 4 C. parapsilosis 5 C. lusitaniae - 2 C. krusei - 0 C. glabrata - 1 C. tropicalis 1 VOLUME XXIX NUMBER 3 November 2014 Page 7
8 Table 7. Cumulative Antimicrobial Susceptibility Report for Anaerobic Organisms Isolates collected from US hospitals January 1, 2007 December 31, 2009 ANAEROBIC Ampicillin-sulbactam (Unasyn) Piperacillin/tazobactam (Zosyn) Cefoxitin Ertapenem Meropenem Penicillin/ampicillin Clindamycin Metronidazole Percent Susceptible (%S) and %S %R %S %R %S %R %S %R %S %R %S %R %S %R %S %R Percent Resistant (%R) Fusobacterium nucleatum * necrophorum Anaerobic gram- positive * cocci P. acnes * B. fragilis group *% S for meropenem is not reported due to lack of data and breakpoints are not well established. Data adapted from CLSI M100-S23 January VOLUME XXIX NUMBER 3 November 2014 Page 8
9 We are modifying our distribution process for Contagious Comments. If you wish to receive this publication please provide us with your E mail address below. Name: E mail Address: Both the Contagious Comments and Bug Watch publications are always posted on Children s Hospital Colorado website at: Please return your E mail address to: Carolyn Brock, Children s Hospital Colorado, Epidemiology Box B276, E. 16 th Avenue, Aurora, CO or E mail address: carolyn.brock@childrenscolorado.org. Thank you for your interest in our publication. CONTAGIOUS COMMENTS Department of Epidemiology EDITOR: Carolyn Brock, Program Assistant Children s Hospital Colorado, Dept. of Epidemiology, B E. 16th Avenue, Aurora, CO Phone: (720) ; FAX: (720) carolyn.brock@childrenscolorado.org ** We Recycle! ** VOLUME XXIX NUMBER 3 November 2014 Page 9
CONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXVII NUMBER 6 July 2012 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine B. Dowell SM, MLS (ASCP); Sarah K. Parker, MD; James K. Todd, MD Each year the Children s Hospital Colorado
More informationINFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More information2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital
2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationAberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015
Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More information2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital
2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationTable 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationRCH antibiotic susceptibility data
RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationAntimicrobial Susceptibility Summary 2011
Antimicrobial Susceptibility Summary 2011 Clinical Microbiology Department of Pathology & Laboratory Medicine 45 Antimicrobial Susceptibility Summary Clinical Microbiology Department of Pathology and Laboratory
More informationRecommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data
Recommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data Trevor Van Schooneveld MD, Scott Bergman, PharmD, BCPS, Paul Fey, PhD, Mark Rupp, MD The Clinical Microbiology laboratory
More informationCUMULATIVE ANTIBIOGRAM
BC Children s Hospital and BC Women s Hospital & Health Centre CUMULATIVE ANTIBIOGRAM 2017 Division of Medical Microbiology Department of Pathology and Laboratory Medicine Page 1 of 5 GRAM-POSITIVE BACTERIA
More informationC&W Three-Year Cumulative Antibiogram January 2013 December 2015
C&W Three-Year Cumulative Antibiogram January 213 December 215 Division of Microbiology, Virology & Infection Control Department of Pathology & Laboratory Medicine Contents Comments and Limitations...
More informationLeveraging the Lab and Microbiology Department to Optimize Stewardship
Leveraging the Lab and Microbiology Department to Optimize Stewardship Presented by: Andrew Martinez MLS(ASCP), MT(AMT), MBA Alaska Native Medical Center Microbiology Supervisor Maniilaq Health Center
More informationBactiReg3 Event Notes Module Page(s) 4-9 (TUL) Page 1 of 21
www.wslhpt.org 2601 Agriculture Drive Madison, WI 53718 (800) 462-5261 (608) 265-1111 2015-BactiR Reg3 Shipment Date: September 14, 2015 Questions or comments should be directed to Amanda Weiss at 800-462-5261
More informationAntimicrobial Susceptibility Summary 2012
Antimicrobial Susceptibility Summary 2012 Clinical Microbiology Department of Pathology & Laboratory Medicine 46 53 Antimicrobial Susceptibility Summary Clinical Microbiology Department of Pathology and
More informationUNDERSTANDING THE ANTIBIOGRAM
UNDERSTANDING THE ANTIBIOGRAM April Abbott, PhD, D(ABMM) Deaconess Health System Indiana University School of Medicine - Evansville Evansville, IN April.Abbott@Deaconess.com WHAT WE WILL COVER Describe
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationUNDERSTANDING YOUR DATA: THE ANTIBIOGRAM
UNDERSTANDING YOUR DATA: THE ANTIBIOGRAM April Abbott, PhD, D(ABMM) Deaconess Health System Evansville, IN April.Abbott@Deaconess.com Special thanks to Dr. Shelley Miller for UCLA data WHAT WE WILL COVER
More informationAntimicrobial susceptibility
Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationQUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)
Pseudomonas aeruginosa (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Description: Greenish gray colonies with some beta-hemolysis around each colony on blood agar (BAP),
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationMark Your Calendars Now! Next Event Ships: September 14, 2015
www.wslhpt.org 2601 Agriculture Drive Madison, WI 53718 (800) 462-5261 (608) 265-1111 Shipment Date: June 15, 2015 Questions or comments should be directed to Amanda Weiss at 800-462-5261 x51 or amanda.weiss@slh.wisc.edu.
More informationPrinciples of Infectious Disease. Dr. Ezra Levy CSUHS PA Program
Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,
More informationmicrobiology testing services
microbiology testing services You already know Spectra Laboratories for a wide array of dialysis-related testing services. Now get to know us for your microbiology needs. As the leading provider of renal-specific
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationGuidelines for Laboratory Verification of Performance of the FilmArray BCID System
Guidelines for Laboratory Verification of Performance of the FilmArray BCID System Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes quality standards for all laboratory
More informationThe Nuts and Bolts of Antibiograms in Long-Term Care Facilities
The Nuts and Bolts of Antibiograms in Long-Term Care Facilities J. Kristie Johnson, Ph.D., D(ABMM) Professor, Department of Pathology University of Maryland School of Medicine Director, Microbiology Laboratories
More informationNorthwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16
Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America
More informationPreserve the Power of Antibiotics
PROVIDERInsight News for providers in Northeast Nebraska April 2016 Preserve the Power of Antibiotics Antimicrobial stewardship interventions have been proven to improve individual patient outcomes, reduce
More informationInterpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes
Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes Prof C. Wattal Hon. Sr. Consultant & Chairman Dept. of Clinical Microbiology Sir Ganga Ram Hospital New Delhi
More informationSHC Clinical Pathway: HAP/VAP Flowchart
SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal
More informationEducating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association
More informationAntimicrobial Susceptibility Summary 2017
Antimicrobial Susceptibility Summary 2017 Clinical Microbiology Department of Pathology & Laboratory Medicine Antimicrobial Susceptibility Summary Clinical Microbiology Department of Pathology and Laboratory
More information4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases
4 th and 5 th generation cephalosporins Naderi HR Associate professor of Infectious Diseases Classification Forth generation: Cefclidine, cefepime (Maxipime),cefluprenam, cefoselis,cefozopran, cefpirome
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationSolution Title: Antibiotic Stewardship: A Journey Toward the Triple Aim
Solution Title: Antibiotic Stewardship: A Journey Toward the Triple Aim Program/Project Description, including Goals What was the problem to be solved? How was it identified? What baseline data existed?
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationHUSRES Annual Report 2007 Martti Vaara.
HUSRES Annual Report 2007 Martti Vaara www.huslab.fi www.intra.hus.fi The basis of this HUSRES 2007 report is the HUSLAB/Whonet database 2007, which contains susceptibility data on about 182.000 bacteria
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationPerformance Information. Vet use only
Performance Information Vet use only Performance of plates read manually was measured in three sites. Each centre tested Enterobacteriaceae, streptococci, staphylococci and pseudomonas-like organisms.
More informationPrinciples of Antibiotics Use & Spectrum of Some
Principles of Antibiotics Use & Spectrum of Some Rabee Adwan. MD Infectious Diseases Consultant (Pediatric and Adult) Head Of ID Unit and IPAC Committee- AL-Makassed Hospital-AlQuds Head of IPAC Committee
More information1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient
1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime
More informationAntimicrobial Resistance Trends in the Province of British Columbia
655 West 12th Avenue Vancouver, BC V5Z 4R4 Tel 604.707.2443 Fax 604.707.2441 www.bccdc.ca Antimicrobial Resistance Trends in the Province of British Columbia 2013 Prepared by the Do Bugs Need Drugs? Program
More informationCanadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE FOR HEALTHCARE ACQUIRED CEREBROSPINAL FLUID SHUNT ASSOCIATED INFECTIONS
Canadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE FOR HEALTHCARE ACQUIRED CEREBROSPINAL FLUID SHUNT ASSOCIATED INFECTIONS FINAL November 29, 2017 Working Group: Joanne Langley (Chair),
More informationAdvanced Practice Education Associates. Antibiotics
Advanced Practice Education Associates Antibiotics Overview Difference between Gram Positive(+), Gram Negative(-) organisms Beta lactam ring, allergies Antimicrobial Spectra of Antibiotic Classes 78 Copyright
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationAntimicrobial Stewardship Program
Antimicrobial Stewardship Program David R. Woodard, MSc, FSHEA, CIC CDC: Antibiotic Resistance Threats in the United States, 2013 http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ CDC Threat Levels
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More informationYork Chairman David B. Jones, MD
York Chairman David B. Jones, MD Pathologists Abby W. Davis, MD David A. Derrick, MD J. Ander Pindzola, MD John A. Wright, MD Stanley D. Hurtt, MD Matthew F. Georgy, MD Michelle L. Erickson, MD, MBA William
More information5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)
Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health
More informationAntimicrobial Resistance Advisory Workgroup (ARAW) Members
Antimicrobial Resistance Advisory Workgroup (ARAW) Members Jackie Aguilar, BSN, RN Anne Diefendorf, MS, RD Ella Martin, MD Lisa Tibbitts, RN, BSN, MSNed, BC Bobbie Bagley, RN, MS, MCH, CPH Apara Dave,
More informationPenicillins - EUCAST clinical MIC breakpoints (version 1.3)
EUCAST clinical MIC breakpoints - penicillins Penicillins - EUCAST clinical MIC breakpoints 2009-04-19 (version 1.3) Penicillins Click on antibiotic name to see wild type MIC distributions. Enterobacteriaceae
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationHelen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
METHODS USED IN NEW ZEALAND DIAGNOSTIC LABORATORIES TO IDENTIFY AND REPORT EXTENDED-SPECTRUM β-lactamase- PRODUCING ENTEROBACTERIACEAE by Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
More informationPerichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV
Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,
More informationBugs and Drugs Handbook 2017
Bugs and Drugs Handbook 2017 Allegra CdeBaca Age 8 Table of Contents How to Improve Infectious Disease Outcomes and Reduce Costs Sutton s Law: Culture Where the Infection Is!... 1 Legend for Antimicrobial
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationSurveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level. janet hindler
Surveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level janet hindler At the conclusion of this talk, you will be able to Describe CLSI M39-A3 recommendations
More informationMedicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!
Medicinal Chemistry 561P 2 st hour Examination May 6, 2013 NAME: KEY Good Luck! 2 MDCH 561P Exam 2 May 6, 2013 Name: KEY Grade: Fill in your scantron with the best choice for the questions below: 1. Which
More informationBacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching Hospital, Bengaluru, India
ISSN: 2319-7706 Volume 4 Number 11 (2015) pp. 731-736 http://www.ijcmas.com Original Research Article Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching
More informationADC 2016 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao
ADC 216 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao Willemstad, November 217 Authors: Radjin Steingrover clinical microbiologist, head dpt. Microbiology ADC
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland
More informationEUCAST-and CLSI potency NEO-SENSITABS
EUCASTand CLSI potency NEOSENSITABS Neo Sensitabs Page 1 / 6 Document: 6.2.0 Fastidious organisms EUCAST Interpretation zones and MIC breakpoints according to recommendations by the "Comité de l'antibiogramme
More informationSuper Bugs and Wonder Drugs: Protecting the One While Respecting the Many
Super Bugs and Wonder Drugs: Protecting the One While Respecting the Many Vicki Stringfellow, MSN, CPNP-AC/PC Werner Division of Pediatric Critical Care University of Kentucky Lexington, KY Disclosure
More informationAntimicrobial Resistance Trends in the Province of British Columbia. August Epidemiology Services British Columbia Centre for Disease Control
Antimicrobial Resistance Trends in the Province of British Columbia August 2008 Epidemiology Services British Columbia Centre for Disease Control 5 Table of Contents Executive Summary...5 Objective...6
More information* gender factor (male=1, female=0.85)
Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12
More information